Market Research Logo

Alzheimer’s Disease - Pipeline Review, H1 2016

Table of Contents
Introduction
Alzheimer’s Disease Overview
Therapeutics Development
Alzheimer’s Disease - Therapeutics under Development by Companies
Alzheimer’s Disease - Therapeutics under Investigation by Universities/Institutes
Alzheimer’s Disease - Pipeline Products Glance
Alzheimer’s Disease - Products under Development by Companies
Alzheimer’s Disease - Products under Investigation by Universities/Institutes
Alzheimer’s Disease - Companies Involved in Therapeutics Development
Alzheimer’s Disease - Therapeutics Assessment
Drug Profiles
Alzheimer’s Disease - Recent Pipeline Updates
Alzheimer’s Disease - Dormant Projects
Alzheimer’s Disease - Discontinued Products
Alzheimer’s Disease - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Alzheimer’s Disease, H1 2016
Number of Products under Development for Alzheimer’s Disease - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Development by Companies, H1 2016 (Contd..1)
Number of Products under Development by Companies, H1 2016 (Contd..2)
Number of Products under Development by Companies, H1 2016 (Contd..3)
Number of Products under Development by Companies, H1 2016 (Contd..4)
Number of Products under Development by Companies, H1 2016 (Contd..5)
Number of Products under Development by Companies, H1 2016 (Contd..6)
Number of Products under Development by Companies, H1 2016 (Contd..7)
Number of Products under Development by Companies, H1 2016 (Contd..8)
Number of Products under Development by Companies, H1 2016 (Contd..9)
Number of Products under Development by Companies, H1 2016 (Contd..10)
Number of Products under Development by Companies, H1 2016 (Contd..11)
Number of Products under Development by Companies, H1 2016 (Contd..12)
Number of Products under Development by Companies, H1 2016 (Contd..13)
Number of Products under Development by Companies, H1 2016 (Contd..14)
Number of Products under Development by Companies, H1 2016 (Contd..15)
Number of Products under Development by Companies, H1 2016 (Contd..16)
Number of Products under Development by Companies, H1 2016 (Contd..17)
Number of Products under Investigation by Universities/Institutes, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..6)
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Comparative Analysis by Unknown Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Products under Development by Companies, H1 2016 (Contd..2)
Products under Development by Companies, H1 2016 (Contd..3)
Products under Development by Companies, H1 2016 (Contd..4)
Products under Development by Companies, H1 2016 (Contd..5)
Products under Development by Companies, H1 2016 (Contd..6)
Products under Development by Companies, H1 2016 (Contd..7)
Products under Development by Companies, H1 2016 (Contd..8)
Products under Development by Companies, H1 2016 (Contd..9)
Products under Development by Companies, H1 2016 (Contd..10)
Products under Development by Companies, H1 2016 (Contd..11)
Products under Development by Companies, H1 2016 (Contd..12)
Products under Development by Companies, H1 2016 (Contd..13)
Products under Development by Companies, H1 2016 (Contd..14)
Products under Development by Companies, H1 2016 (Contd..15)
Products under Development by Companies, H1 2016 (Contd..16)
Products under Development by Companies, H1 2016 (Contd..17)
Products under Development by Companies, H1 2016 (Contd..18)
Products under Development by Companies, H1 2016 (Contd..19)
Products under Development by Companies, H1 2016 (Contd..20)
Products under Development by Companies, H1 2016 (Contd..21)
Products under Development by Companies, H1 2016 (Contd..22)
Products under Development by Companies, H1 2016 (Contd..23)
Products under Development by Companies, H1 2016 (Contd..24)
Products under Development by Companies, H1 2016 (Contd..25)
Products under Development by Companies, H1 2016 (Contd..26)
Products under Investigation by Universities/Institutes, H1 2016
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2016 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2016 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2016 (Contd..5)
Products under Investigation by Universities/Institutes, H1 2016 (Contd..6)
Products under Investigation by Universities/Institutes, H1 2016 (Contd..7)
Products under Investigation by Universities/Institutes, H1 2016 (Contd..8)
Products under Investigation by Universities/Institutes, H1 2016 (Contd..9)
Alzheimer’s Disease - Pipeline by AB Science SA, H1 2016
Alzheimer’s Disease - Pipeline by AbbVie Inc., H1 2016
Alzheimer’s Disease - Pipeline by AC Immune SA, H1 2016
Alzheimer’s Disease - Pipeline by Accera, Inc., H1 2016
Alzheimer’s Disease - Pipeline by Acelot, Inc., H1 2016
Alzheimer’s Disease - Pipeline by Actinogen Limited, H1 2016
Alzheimer’s Disease - Pipeline by Acumen Pharmaceuticals, Inc., H1 2016
Alzheimer’s Disease - Pipeline by Addex Therapeutics Ltd, H1 2016
Alzheimer’s Disease - Pipeline by Affibody AB, H1 2016
Alzheimer’s Disease - Pipeline by AFFiRiS AG, H1 2016
Alzheimer’s Disease - Pipeline by Alector LLC, H1 2016
Alzheimer’s Disease - Pipeline by Alkermes Plc, H1 2016
Alzheimer’s Disease - Pipeline by ALSP, Inc., H1 2016
Alzheimer’s Disease - Pipeline by Alzhyme Pty Ltd, H1 2016
Alzheimer’s Disease - Pipeline by Alzinova AB, H1 2016
Alzheimer’s Disease - Pipeline by AlzProtect SAS, H1 2016
Alzheimer’s Disease - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016
Alzheimer’s Disease - Pipeline by Amgen Inc., H1 2016
Alzheimer’s Disease - Pipeline by Anavex Life Sciences Corp., H1 2016
Alzheimer’s Disease - Pipeline by Aphios Corporation, H1 2016
Alzheimer’s Disease - Pipeline by Apodemus AB, H1 2016
Alzheimer’s Disease - Pipeline by Applied Research using OMIC Sciences, S.L., H1 2016
Alzheimer’s Disease - Pipeline by Araclon Biotech, S.L., H1 2016
Alzheimer’s Disease - Pipeline by Archer Pharmaceuticals, Inc., H1 2016
Alzheimer’s Disease - Pipeline by ArmaGen Inc., H1 2016
Alzheimer’s Disease - Pipeline by Artery Therapeutics, Inc., H1 2016
Alzheimer’s Disease - Pipeline by AskAt Inc., H1 2016
Alzheimer’s Disease - Pipeline by Astellas Pharma Inc., H1 2016
Alzheimer’s Disease - Pipeline by AstraZeneca Plc, H1 2016
Alzheimer’s Disease - Pipeline by Asubio Pharma Co., Ltd., H1 2016
Alzheimer’s Disease - Pipeline by Ausio Pharmaceuticals, LLC, H1 2016
Alzheimer’s Disease - Pipeline by Avineuro Pharmaceuticals, Inc., H1 2016
Alzheimer’s Disease - Pipeline by Axerion Therapeutics, Inc., H1 2016
Alzheimer’s Disease - Pipeline by Axon Neuroscience SE, H1 2016
Alzheimer’s Disease - Pipeline by Axovant Sciences Ltd., H1 2016
Alzheimer’s Disease - Pipeline by Axsome Therapeutics, Inc., H1 2016
Alzheimer’s Disease - Pipeline by Axxam SpA, H1 2016
Alzheimer’s Disease - Pipeline by Beactica AB, H1 2016
Alzheimer’s Disease - Pipeline by Berg LLC, H1 2016
Alzheimer’s Disease - Pipeline by BioArctic Neuroscience AB, H1 2016
Alzheimer’s Disease - Pipeline by Bioasis Technologies Inc., H1 2016
Alzheimer’s Disease - Pipeline by Biogen, Inc., H1 2016
Alzheimer’s Disease - Pipeline by Biomar Microbial Technologies, H1 2016
Alzheimer’s Disease - Pipeline by Bionature E.A. Ltd., H1 2016
Alzheimer’s Disease - Pipeline by Boehringer Ingelheim GmbH, H1 2016
Alzheimer’s Disease - Pipeline by Bristol-Myers Squibb Company, H1 2016
Alzheimer’s Disease - Pipeline by Bsim2, H1 2016
Alzheimer’s Disease - Pipeline by Cardax Pharmaceuticals, Inc., H1 2016
Alzheimer’s Disease - Pipeline by Celon Pharma Sp. z o.o., H1 2016
Alzheimer’s Disease - Pipeline by CHA Bio & Diostech Co., Ltd., H1 2016
Alzheimer’s Disease - Pipeline by Chase Pharmaceuticals Corporation, H1 2016
Alzheimer’s Disease - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016
Alzheimer’s Disease - Pipeline by Clera Inc., H1 2016
Alzheimer’s Disease - Pipeline by Cognition Therapeutics, Inc., H1 2016
Alzheimer’s Disease - Pipeline by Cognosci, Inc., H1 2016
Alzheimer’s Disease - Pipeline by CohBar, Inc., H1 2016
Alzheimer’s Disease - Pipeline by CoLucid Pharmaceuticals, Inc., H1 2016
Alzheimer’s Disease - Pipeline by Connexios Life Sciences Pvt. Ltd., H1 2016
Alzheimer’s Disease - Pipeline by Corium International, Inc., H1 2016
Alzheimer’s Disease - Pipeline by Coronis Partners Ltd., H1 2016
Alzheimer’s Disease - Pipeline by Critical Outcome Technologies Inc., H1 2016
Alzheimer’s Disease - Pipeline by Crossbeta Biosciences B.V., H1 2016
Alzheimer’s Disease - Pipeline by D-Pharm Ltd., H1 2016
Alzheimer’s Disease - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016
Alzheimer’s Disease - Pipeline by Daval International Limited, H1 2016
Alzheimer’s Disease - Pipeline by DermaXon, LLC, H1 2016
Alzheimer’s Disease - Pipeline by Domain Therapeutics SA, H1 2016
Alzheimer’s Disease - Pipeline by Eisai Co., Ltd., H1 2016
Alzheimer’s Disease - Pipeline by Eli Lilly and Company, H1 2016
Alzheimer’s Disease - Pipeline by EncephRx, Inc., H1 2016
Alzheimer’s Disease - Pipeline by ENKAM Pharmaceuticals A/S, H1 2016
Alzheimer’s Disease - Pipeline by Ensemble Therapeutics Corporation, H1 2016
Alzheimer’s Disease - Pipeline by Ensol Biosciences Inc., H1 2016
Alzheimer’s Disease - Pipeline by Epigen Biosciences, Inc., H1 2016
Alzheimer’s Disease - Pipeline by Euroscreen S.A., H1 2016
Alzheimer’s Disease - Pipeline by Evotec AG, H1 2016
Alzheimer’s Disease - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
Alzheimer’s Disease - Pipeline by FORUM Pharmaceuticals Inc., H1 2016
Alzheimer’s Disease - Pipeline by Genentech, Inc., H1 2016
Alzheimer’s Disease - Pipeline by Genervon Biopharmaceuticals, LLC, H1 2016
Alzheimer’s Disease - Pipeline by GlaxoSmithKline Plc, H1 2016
Alzheimer’s Disease - Pipeline by GliaCure Inc., H1 2016
Alzheimer’s Disease - Pipeline by Golden Biotechnology Corp., H1 2016
Alzheimer’s Disease - Pipeline by Grifols, S.A., H1 2016
Alzheimer’s Disease - Pipeline by H. Lundbeck A/S, H1 2016
Alzheimer’s Disease - Pipeline by Heptares Therapeutics Limited, H1 2016
Alzheimer’s Disease - Pipeline by Herantis Pharma Plc, H1 2016
Alzheimer’s Disease - Pipeline by Humanetics Corporation, H1 2016
Alzheimer’s Disease - Pipeline by Ichor Medical Systems, Inc., H1 2016
Alzheimer’s Disease - Pipeline by Icure Pharmaceutical Inc., H1 2016
Alzheimer’s Disease - Pipeline by Immungenetics AG, H1 2016
Alzheimer’s Disease - Pipeline by Immunome Inc., H1 2016
Alzheimer’s Disease - Pipeline by Impel NeuroPharma, Inc., H1 2016
Alzheimer’s Disease - Pipeline by ImStar Therapeutics Inc., H1 2016
Alzheimer’s Disease - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016
Alzheimer’s Disease - Pipeline by IntelGenx Corp., H1 2016
Alzheimer’s Disease - Pipeline by Intellect Neurosciences, Inc., H1 2016
Alzheimer’s Disease - Pipeline by Intra-Cellular Therapies, Inc., H1 2016
Alzheimer’s Disease - Pipeline by INVENT Pharmaceuticals, Inc., H1 2016
Alzheimer’s Disease - Pipeline by Io Therapeutics, Inc., H1 2016
Alzheimer’s Disease - Pipeline by Iproteos S.L., H1 2016
Alzheimer’s Disease - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016
Alzheimer’s Disease - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2016
Alzheimer’s Disease - Pipeline by Johnson & Johnson, H1 2016
Alzheimer’s Disease - Pipeline by K-Stemcell Co., Ltd., H1 2016
Alzheimer’s Disease - Pipeline by Kadmon Corporation, LLC, H1 2016
Alzheimer’s Disease - Pipeline by Kalgene Pharmaceuticals Inc., H1 2016
Alzheimer’s Disease - Pipeline by Kareus Therapeutics, SA, H1 2016
Alzheimer’s Disease - Pipeline by KineMed, Inc., H1 2016
Alzheimer’s Disease - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016
Alzheimer’s Disease - Pipeline by Lead Discovery Center GmbH, H1 2016
Alzheimer’s Disease - Pipeline by Les Laboratoires Servier SAS, H1 2016
Alzheimer’s Disease - Pipeline by Lipopharma Therapeutics SL, H1 2016
Alzheimer’s Disease - Pipeline by Living Cell Technologies Limited, H1 2016
Alzheimer’s Disease - Pipeline by Lupin Limited, H1 2016
Alzheimer’s Disease - Pipeline by M3 Biotechnology, Inc., H1 2016
Alzheimer’s Disease - Pipeline by ManRos Therapeutics, H1 2016
Alzheimer’s Disease - Pipeline by MedDay, H1 2016
Alzheimer’s Disease - Pipeline by Medestea Research & Production S.p.A., H1 2016
Alzheimer’s Disease - Pipeline by MedImmune, LLC, H1 2016
Alzheimer’s Disease - Pipeline by Medisyn Technologies, Inc., H1 2016
Alzheimer’s Disease - Pipeline by Merck & Co., Inc., H1 2016
Alzheimer’s Disease - Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2016
Alzheimer’s Disease - Pipeline by Metabolic Solutions Development Company, LLC, H1 2016
Alzheimer’s Disease - Pipeline by Mithridion, Inc., H1 2016
Alzheimer’s Disease - Pipeline by NAL Pharmaceuticals Ltd., H1 2016
Alzheimer’s Disease - Pipeline by Nanomerics Ltd, H1 2016
Alzheimer’s Disease - Pipeline by Nanotherapeutics, Inc., H1 2016
Alzheimer’s Disease - Pipeline by Neuralstem, Inc., H1 2016
Alzheimer’s Disease - Pipeline by Neuraltus Pharmaceuticals, Inc., H1 2016
Alzheimer’s Disease - Pipeline by Neurim Pharmaceuticals Ltd, H1 2016
Alzheimer’s Disease - Pipeline by Neurodyn Inc., H1 2016
Alzheimer’s Disease - Pipeline by NeuroGeneration, Inc., H1 2016
Alzheimer’s Disease - Pipeline by NeuroGenetic Pharmaceuticals, Inc., H1 2016
Alzheimer’s Disease - Pipeline by NeuroNascent, Inc., H1 2016
Alzheimer’s Disease - Pipeline by Neuronax SAS, H1 2016
Alzheimer’s Disease - Pipeline by NeurOp, Inc, H1 2016
Alzheimer’s Disease - Pipeline by NeuroPhage Pharmaceuticals, Inc., H1 2016
Alzheimer’s Disease - Pipeline by Neuropore Therapies, Inc., H1 2016
Alzheimer’s Disease - Pipeline by Neurotez, Inc., H1 2016
Alzheimer’s Disease - Pipeline by New World Laboratories, Inc., H1 2016
Alzheimer’s Disease - Pipeline by nLife Therapeutics, S.L., H1 2016
Alzheimer’s Disease - Pipeline by NLS Pharma Group, H1 2016
Alzheimer’s Disease - Pipeline by Novartis AG, H1 2016
Alzheimer’s Disease - Pipeline by Oligomerix, inc., H1 2016
Alzheimer’s Disease - Pipeline by Oryzon Genomics S.A., H1 2016
Alzheimer’s Disease - Pipeline by P2D Bioscience, H1 2016
Alzheimer’s Disease - Pipeline by Pain Therapeutics, Inc., H1 2016
Alzheimer’s Disease - Pipeline by Palumed S.A., H1 2016
Alzheimer’s Disease - Pipeline by Panacea Pharmaceuticals, Inc., H1 2016
List of Figures
Number of Products under Development for Alzheimer’s Disease, H1 2016
Number of Products under Development for Alzheimer’s Disease - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Top 10 Routes of Administration, H1 2016
Number of Products by Stage and Top 10 Routes of Administration, H1 2016
Number of Products by Top 10 Molecule Types, H1 2016
Number of Products by Stage and Top 10 Molecule Types, H1 2016

Alzheimer’s Disease - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Alzheimer’s Disease - Pipeline Review, H1 2016’, provides an overview of the Alzheimer’s Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Alzheimer’s Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alzheimer’s Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Alzheimer’s Disease
The report reviews pipeline therapeutics for Alzheimer’s Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved Alzheimer’s Disease therapeutics and enlists all their major and minor projects
The report assesses Alzheimer’s Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news related to pipeline therapeutics for Alzheimer’s Disease

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Alzheimer’s Disease
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Alzheimer’s Disease pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;